JANUARY 1 – DECEMBER 31, 2008
• Net sales for the period totaled SEK 62.7 M (64.7)
• Profit after tax was SEK 18.2 M (19.8)
• Earnings per share amounted to SEK 0.53 (0.58)
• Operating profit was SEK 21.1 M (25.8)
• Cash flow from operating activities totaled SEK 26.0 M (37.9)
• An agreement with Philips covering a product for the new treatment method VMAT was reached in June
• A cooperation agreement covering research within multi-criteria optimization with Massachusetts General Hospital in Boston, U.S., was signed in August
• The first patient was treated using RaySearch’s system for proton therapy in December
• The Board proposes that no dividend be paid
AFTER THE CLOSE OF THE PERIOD
• The collaboration with Nucletron was extended in January with two new solutions for treatment planning
• The first product from the collaboration with TomoTherapy received FDA clearance in January and can therefore be launched
“It is highly pleasing that 2008 ended with the highest quarterly revenues in RaySearch’s history. As a result, nearly the entire sales dip in the sluggish second and third quarters was offset,” comments Johan Löf, President and CEO of RaySearch.
“2009 will be a record year in terms of new products, with market launches by all our five partners. The number of revenue-generating products is therefore expected to almost double during the year,” concludes Johan Löf.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President and CEO
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com
Financial Reports
